Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-
Sermorelin Injections: Sites and Expectations
Sermorelin is injected into the fatty layer beneath the skin, commonly around bedtime. The dose, schedule, site plan, and storage instructions come from the prescriber and dispensing pharmacy—not a universal online protocol.
-
SS-31 Benefits: What Human Trials Actually Show
The clearest human evidence for SS-31 is narrow: muscle-strength findings in people with Barth syndrome. Larger trials in other mitochondrial, heart, and eye conditions have produced mixed or negative primary results.
-
TB-500 Benefits: What the Evidence Shows
TB-500 benefits are biologically plausible but not established in people. Direct evidence is largely laboratory and animal work on a related actin-binding sequence; the human eye and wound trials tested full-length thymosin beta-4, not systemic TB-500.
-
Tirzepatide Injections: A Practical Guide
Tirzepatide injections deliver prescribed tirzepatide under the skin once weekly. The device may be a prefilled pen, a four-dose KwikPen, or a vial used with a syringe, and each format has its own instructions.
-
Does Semaglutide Cause Depression? What We Know
Large trials, cohort studies, and final FDA and European reviews have not found that semaglutide raises depression or suicidality risk. Individual mood changes still deserve prompt attention.
-
GHK-Cu Dosage: How Prescribers Set the Amount
There is no validated human injection dose for GHK-Cu. Topical studies disclose several concentrations, while compounded injection amounts come from clinical practice and must be tied to the exact vial and the person being treated.
-
Peptides With Semaglutide: What the Evidence Says
Evidence gaps depend on the specific peptide combined with semaglutide; [cagrilintide–semaglutide has randomized phase 3 trial data](https://pubmed.ncbi.nlm.nih.gov/40544433/), while the combinations discussed here do not. A provider has to judge each compound on its own evidence, risks, and purpose.
-
Semaglutide and Pancreatitis: What Studies Show
Randomized trials have not shown more acute pancreatitis with semaglutide than with placebo, but the event is rare and remains a prescribing-label warning. Persistent, severe abdominal pain needs prompt medical attention.
-
Semaglutide for Fatty Liver: What Evidence Shows
Semaglutide has strong biopsy-based evidence in adults with MASH and F2–F3 fibrosis. That is narrower than “fatty liver,” and it does not make every semaglutide formulation interchangeable.
-
Thymosin Alpha-1 Side Effects: What Trials Found
Published trials most consistently report local injection-site discomfort; fatigue and rash are uncommon and often hard to attribute. The limits are long-term exposure and the difference between studied thymalfasin and a compounded vial.
-
Tirzepatide Pyridoxine: What Vitamin B6 Adds
Tirzepatide/pyridoxine is a compounded combination of tirzepatide and vitamin B6. The B6 is usually included with nausea in mind, but no clinical trial has shown that the combination works better than tirzepatide alone.
-
DSIP Side Effects: What Human Studies Found
Reported DSIP side effects include sleep pressure, headache, nausea, vertigo, sweating and occasional blood-pressure changes, but small, short studies leave long-term risk largely unknown.
-
Peptides vs Steroids: What Makes Them Different?
Peptides and anabolic steroids are different molecules with different targets, evidence, risks, and legal status. A peptide is not simply a steroid under a newer name.
-
PT-141 for Men: What the Male Studies Show
PT-141 produced measurable erectile responses in early male trials, including studies involving men who reported an inadequate response to sildenafil. The evidence is limited, route-specific, and not the same as an established male indication.
-
Semaglutide Before Surgery: Do You Need to Stop?
Most patients can continue semaglutide before an elective procedure, but the plan changes when delayed stomach emptying is more likely. The anesthesia and prescribing teams should make that call together.
-
Semaglutide Drug Interactions: What Matters
Most semaglutide interactions are not classic liver-enzyme conflicts. The practical concerns are low blood sugar with insulin or sulfonylureas and altered absorption of oral medicines that need tightly controlled exposure.
-
Semaglutide Sulfur Burps: Why They Happen
Sulfur-smelling burps are a real but poorly measured digestive complaint with semaglutide. Trials counted belching, not its smell, and the likely explanation combines slower digestion with hydrogen-sulfide gas.
-
Tesamorelin for Belly Fat: What the Studies Show
Tesamorelin has reduced visceral abdominal fat in randomized trials, most convincingly in adults with HIV-associated lipodystrophy. That evidence does not make it a general weight-loss drug or a reliable way to shrink the fat just under the skin.
-
Tirzepatide for PCOS: What the Evidence Shows
Early studies connect tirzepatide with weight and metabolic changes in people with PCOS, but the direct evidence is still small. Pregnancy plans and the reason for prescribing matter as much as the diagnosis.
-
BPC-157 for Inflammation: What the Evidence Shows
Rodent studies report smaller gut lesions, lower oxidative-stress measures and altered inflammatory signaling. No human trial has shown that BPC-157 lowers inflammation.
Page 8 of 12 · 227 articles